These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 23026844

  • 1. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J, Tolley K, Vieira J, Chandiwana D.
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Pharmacoeconomics; 2007 Dec; 25(4):329-42. PubMed ID: 17402805
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R.
    Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q.
    J Med Econ; 2010 Jun; 13(3):559-70. PubMed ID: 20812793
    [Abstract] [Full Text] [Related]

  • 5. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 6. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
    Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P.
    Clin Drug Investig; 2011 Aug; 31(7):493-505. PubMed ID: 21627338
    [Abstract] [Full Text] [Related]

  • 7. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL, Chung KP, Yang SS, Lu MY, Jou ST, Chang HH, Yang YL, Lin DT, Lin KH.
    J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A, Gillard S, Spino M, Connelly J, Tricta F.
    Pharmacoeconomics; 2013 Sep 15; 31(9):807-22. PubMed ID: 23868464
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F, Phatak P.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug 15; 9(4):297-304. PubMed ID: 19670988
    [Abstract] [Full Text] [Related]

  • 14. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 15. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.
    Kim J, Kim Y.
    Value Health; 2009 May 01; 12 Suppl 3():S78-81. PubMed ID: 20586988
    [Abstract] [Full Text] [Related]

  • 16. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 17. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 18. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, Cuccia L, Spasiano A, Filosa A, Caruso V, Hanif A, Meloni A.
    Clin Drug Investig; 2017 May 15; 37(5):453-464. PubMed ID: 28185140
    [Abstract] [Full Text] [Related]

  • 19. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May 15; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 20. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD, Taher A.
    Expert Opin Pharmacother; 2008 Sep 15; 9(13):2391-402. PubMed ID: 18710363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.